IBD Prediction Is Possible, but How Far Are We from Implementing It?

Crohn's disease and ulcerative colitis, collectively known as inflammatory bowel diseases (IBDs), are chronic gastrointestinal diseases with poorly characterized pathophysiology. Recent advancements in the identification of preclinical biomarkers of IBD have shed some insight into our ability to predict or prevent these conditions. This review discusses the growing body of research on biomarkers ranging from genetics, measures of gut permeability, and microbiome signatures to circulating proteomics and metabolomics. In addition, the review will highlight the potential application of these biomarkers for early detection and risk stratification of IBD. Notably, proteomic markers such as CXCL9 and MMP-10, along with metabolic perturbations detectable prior to clinical diagnosis, provide promising avenues for understanding IBD pathogenesis and guiding prevention strategies. Furthermore, the development of integrative risk scores, combining multiomic data with demographic and lifestyle factors, could offer a personalized approach to disease prediction and prevention. While these advances present significant opportunities, challenges remain in data complexity and variability of biomarkers. This review emphasizes the importance of continued longitudinal studies and clinical trials to validate predictive models. Ultimately, the integration of early risk prediction holds the potential to reduce IBD incidence through targeted, proactive strategies.